Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

NCT03008109 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

80

Enrollment

OTHER_GOV

Sponsor class

Conditions

Advanced Cancer
Lung Cancer, Nonsmall Cell

Interventions

DRUG: EGFR-TK Inhibitor

Sponsor

Zaiwen Fan